Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53.

MLA

Ou, Wen-Bin, et al. “Co-Targeting of FAK and MDM2 Triggers Additive Anti-Proliferative Effects in Mesothelioma via a Coordinated Reactivation of P53.” British Journal of Cancer, vol. 115, no. 10, Nov. 2016, pp. 1253–63. EBSCOhost, https://doi.org/10.1038/bjc.2016.331.

APA

Ou, W.-B., Lu, M., Eilers, G., Li, H., Ding, J., Meng, X., Wu, Y., He, Q., Sheng, Q., Zhou, H.-M., & Fletcher, J. A. (2016). Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53. British Journal of Cancer, 115(10), 1253–1263. https://doi.org/10.1038/bjc.2016.331

Chicago

Ou, Wen-Bin, Minmin Lu, Grant Eilers, Hailong Li, Jiongyan Ding, Xuli Meng, Yuehong Wu, et al. 2016. “Co-Targeting of FAK and MDM2 Triggers Additive Anti-Proliferative Effects in Mesothelioma via a Coordinated Reactivation of P53.” British Journal of Cancer 115 (10): 1253–63. doi:10.1038/bjc.2016.331.